Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211978 · ClinicalTrials.gov registry record · Phase 3
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT00211978 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 110 participants.
The verdict
NCT00211978, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
Interventions
- DRUG placebo
- DRUG calcium acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211978
The ClinicalTrials.gov registry entry for NCT00211978 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00211978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211978 about?
NCT00211978 is a clinical study titled "EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)". The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
What is the current status of trial NCT00211978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2005-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00211978?
The interventions under investigation include: placebo (DRUG), calcium acetate (DRUG).
Who is sponsoring clinical trial NCT00211978?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.